In conclusion, the provision of timely information on SMN1 and confirmation of disease status, along with SMN2 copy number, as part of a SMA newborn-screening program can significantly improve clinical follow-up, testing of family members, and treatment of SMA patients. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.